)
Edge
Extra Everything: The Story of Chipotle
Chipotle's story from a single restaurant to a nationwide chain, through crisis and turnaround, built on one of the strongest models in the industry.
Arovella Therapeutics
Arovella Therapeutics (ALA) investor relations material
Arovella Therapeutics Corporate presentation summary
Complete event summary combining all related documents: earnings call transcript, report, and slide presentation.Corporate presentation summary7 May, 2026
Investment highlights and leadership
U.S. FDA IND accepted for ALA-101, with phase 1 trials for CD19-positive blood cancers expected in FY 2026.
Developing off-the-shelf iNKT cell therapies for blood and solid tumour cancers.
Proprietary clinic-ready manufacturing process for CAR-iNKT cells established.
Strategic acquisitions and a leadership team with proven cell therapy experience.
Strong scientific and clinical advisory boards with global experts.
Financial overview
Market capitalisation of $104.58 million as of January 2025, with $19.4 million cash at 31 Dec 2025.
Major shareholders include Biotech Capital Management (5.78%) and Richard John Mann (5.76%).
Share price ranged from $0.068 to $0.195 over the past year.
Cell therapy market and technology
CAR-T therapies have revolutionised blood cancer treatment, with a market expected to reach $15.2 billion by 2035.
Current CAR-T therapies are patient-specific, costly, and slow to manufacture.
iNKT cells offer off-the-shelf potential, strong safety, and do not cause GVHD.
iNKT cells bridge innate and adaptive immunity, naturally target cancer, and modulate the tumour microenvironment.
Partial view of Summaries dataset, powered by Quartr API
AI can get things wrong. Verify important information.Research faster. Power your platform.
Latest events from Arovella Therapeutics
- IND clearance and strong cash position support clinical trial launch for lead cell therapy.ALA
Q3 2026 TU3 May 2026 - Net loss narrowed 14% to $7.5M as revenue rose 700% and cash reserves reached $20.9M.ALAH2 20256 Apr 2026
- Cash reserves rose and clinical progress continued, with Phase 1 trials for ALA-101 expected in FY2025.ALAH2 20246 Apr 2026
- Losses increased and revenue declined, but clinical and cash milestones were achieved.ALAH1 20268 Mar 2026
- IND filed for ALA-101, Phase 1 trial set for 2026, $19.4M cash, and robust pipeline expansion.ALAQ2 2026 TU23 Jan 2026
- Clinical and strategic milestones achieved as CAR-iNKT pipeline advances toward trials.ALAAGM 202529 Dec 2025
- Strong cash position and clinical progress with ALA-101 and ALA-105 programs, plus new US patent.ALAQ1 2026 TU7 Dec 2025
- $23.5M cash and $15M raise secure phase I trial and pipeline progress for 2025 milestones.ALAQ3 202528 Nov 2025
- Two placement-related resolutions were voted on, with results to be released on ASX.ALAEGM 202527 Nov 2025
Arovella Therapeutics
The essential earnings season companion
The #1 app for qualitative research. Live earnings calls, AI chat, transcripts, and more. All for free.
Live calls and transcripts
Listen to earnings calls, CMDs, investor conferences, and more – with a podcast-like experience.
Find what you need faster
Search for any keyword across all transcripts simultaneously.
Easily store key findings
Capturing important takeaways is as simple as it gets. Even during your lunch run or commute.
Your watchlist. Your dashboard.
Follow the companies that matter to you. Get a personalized feed with real-time updates.
Be the first to know
Set keyword alerts for any company, product, or competitor. Get notified the moment they're mentioned.
Consensus estimates
Access analyst consensus estimates, valuation multiples, and revenue segments splits.
All IR material in one place
The easiest way to stay updated during earnings season.
Global coverage
All events from public companies. Live and recorded.
Just click and listen
No webcast links. No manual registrations.
excellent app, it gives me free access to company earnings calls and annual reports. I also love the convenience of calls being available offline so I can listen in whilst doing other things and even when internet or WiFi isn't available.
)
Leroy DaleyApp Store
One of the very few apps you could call perfect. If something was to add to it, maybe the share price of the company when you search for it, but it's already excellent.
)
Eferix Drawings Google Play
This is genuinely one of the cleanest and fastest finance apps out there to track the market.
anuj283App Store
excellent app, it gives me free access to company earnings calls and annual reports. I also love the convenience of calls being available offline so I can listen in whilst doing other things and even when internet or WiFi isn't available.
Leroy DaleyApp Store
One of the very few apps you could call perfect. If something was to add to it, maybe the share price of the company when you search for it, but it's already excellent.
Eferix Drawings Google Play
This is genuinely one of the cleanest and fastest finance apps out there to track the market.
anuj283App Store
I can't remember the last time an app had such a positive impact on my investment process.
)
@ankurshah47_ x.com
Love the app! Quartr makes it really easy to keep track of earnings calls. It also includes the reports and slides to make it easier to follow along.
Amina0781App Store
Quartr is amazing, no way around it. It is the best right now for earnings calls, presentations, and the like.
@theshortbearx.com
I can't remember the last time an app had such a positive impact on my investment process.
@ankurshah47_ x.com
Love the app! Quartr makes it really easy to keep track of earnings calls. It also includes the reports and slides to make it easier to follow along.
Amina0781App Store
Quartr is amazing, no way around it. It is the best right now for earnings calls, presentations, and the like.
@theshortbearx.com
Related articles
)
)
Frequently asked questions
Explore our global coverage